tbuckley/cabot-search huggingface dataset:
Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas
Authors: A. Narayana, S. Chheang, E. Knopp, N. Peccerelli, J. Babb, G. Johnson, M. Gruber, J. Allen, D. Zagzag, M. Law
Journal: Journal of Clinical Oncology (2007)

2030 Background: Dynamic susceptibility contrast-enhanced MRI (DSC MRI) is emerging as an important adjunctive biomarker to assess the effectiveness of anti-angiogenic therapies in the treatment of brain tumors. The purpose of our study is to compare changes in relative cerebral blood volume (rCBV) and in perfusion-permeability index (KTrans) with those of tumor volume measurements (T1c, T2/Flair) in predicting tumor therapeutic response in recurrent high-grade gliomas treated with bevacizumab, an anti-VEGF monoclonal antibody. Methods: 11 patients were treated with one to four cycles of bevacizumab and CPT-11. Their histological diagnoses were: glioblastoma multiforme (n=7), anaplastic astrocytoma (n=2), anaplastic oligodendroglioma (n=1), and diffuse pontine glioma (n=1). All patients had baseline DSC MRI scans prior to the administration of bevacizumab and were followed clinically and radiographically with both conventional and DSC MRI. Mixed model regression was used to compare the pre-treatment and post-treatment levels of each response measure. Results: There were statistically significant reductions in both actual rCBV measurements and T1c enhancement following treatment with bevacizumab and CPT-11. The pretreatment rCBV and T1c rates of change (as determined per 100 days) correlated significantly with time (p values are 0.0229 and 0.0014, respectively), while only the post treatment rCBV demonstrated significant rate of change (p value = 0.0001), suggesting that rCBV may reflect the effects of bevacizumab better than tumor volume. However, when the changes in rate from pre- to post-treatment status were considered, both rCBV and T1c demonstrated significance (p= 0.0001, 0.0157, respectively). There was a trend towards females having higher mean levels of KTrans than males at the same time point relative to treatment onset, but the result was not statistically significant (p=0.072). Conclusions: rCBV as measured from DSC MRI can be used as a surrogate biomarker to determine therapeutic response to bevacizumab. This may influence the neurosurgical risk/benefit equation as well as alter the aggressiveness of the post-operative adjuvant therapy in patients with recurrent gliomas. No significant financial relationships to disclose.
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer
Authors: S. Pignata, E. Varriale, G. Casella, F. Iodice, G. De Placido, F. Perrone, F. Tramontana, P. Ricchi, R. DeVivo, R. Costanzo, A. Vernaglia, S. Tramontana
Journal: Annals of Oncology (2000)
Fibroblast growth factor receptor 4 (FGFR4) expression as a prognostic indicator in high-grade serous ovarian carcinoma (HGSC): Signaling pathway, mechanism, and implication for therapeutic targeting.
Authors: T. M. Zaid, M. Thompson, K. Wong, T. Yeung, Z. Yeung, D. M. Gershenson, M. J. Birrer, S. C. Mok
Journal: Journal of Clinical Oncology (2011)

5049 Background: Poor survival associated with the amplicon 5q31-35(previously reported) in HGSC may be due to subsequent overexpression of FGFR4. This work aims to correlate FGFR4 with survival in HGSC, identify its role, molecular mechanism & test feasibility of therapeutic targeting. Methods: QT-PCR validated amplification of FGFR4 on 5q31-35 in 52 cases. IHC quantified FGFR4 expression in 181 patients. Western blots(WB) quantified FGFR4 expression in HGSC cell lines. Role of FGFR4 in proliferation, survival, migration and invasion potential of HGSC in vitro was quantified in HGSC cells transfected with FGFR4 siRNA and control scramble sequence siRNA. HGSC cell lines expressing response elements linked to luciferase were treated with Fibroblast growth factor 1(FGF1) in the presence and absence of FGFR4 siRNA or FGFR4 trap protein to identify relevant pathways. Reverse phase protein array analysis and WB were also performed on HGSC cell lines subjected to similar treatments. Mutational analysis on FGFR4was performed in 43 HGSC samples. Results: FGFR4 staining intensity correlated with poor OS in HGSC patient (median survival 28 vs 55 months p<0.001) and increase risk of death (HR 1.22 p<0.001). FGFR4 was over-expressed in HGSC cell lines compared to ovarian surface epithelium. FGFR4 and FGF1 DNA copy number were significantly correlated (r=0.4, p=0.04). Significant decreases in cell proliferation (p<0.001), survival (p<0.01) and migration (p<0.05) were noted in cells treated with FGFR4 siRNA compared to controls. RPPA, the luciferase reporter assay and western blot analysis demonstrated activation of multiple pathways (MAPK,WNT and NFkB) in response to FGF1 but the effect was inhibited by silencing FGFR4 or by FGFR4 trap treatment. Sequencing of FGFR4 did not reveal mutations. Conclusions: Over-expression of FGFR4 is associated with poor survival in late stage HGSC. In vitro data provides evidence that binding of ligand to FGFR4 activates multiple signaling pathways leading to a more aggressive phenotype. Targeting FGFR4 over-expression in HGSC may be a therapeutic strategy with potential for improving survival in HGSC.
The Efficacy of AR101, a Peanut-Derived Pharmaceutical for Oral Immunotherapy (OIT), Is Maintained and Tolerability Is Increased with Low-Dose Maintenance Therapy
Authors: J. Andrew Bird, Jonathan M. Spergel, Stacie M. Jones, Rima A. Rachid, Amal H. Assa'ad, Julie Wang, Stephanie A. Leonard, Susan Stefanac Laubach, Edwin H. Kim, Benjamin P. Davis, Michael J. Welch, Jennifer Heimall, Antonella Cianferoni, Andrew J. MacGinnitie, Elena Crestani, Sean R. Bennett, Brian P. Vickery, Robert M. Elfont, A. Wesley Burks
Journal: Journal of Allergy and Clinical Immunology (2016)
포스터 발표 : 급성 식도정맥류 출혈 환자에서 내시경적 결찰술과 vasopressin＋nitroglycerin 의 병합요법 및 내시경적 결찰술과 terlipressin 병합요법에 대한 비교 연구
Authors: 이항락, 손주현, 김진배, 김종표, 한동수, 함준수, 이동후, 기춘석
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 급성 식도정맥류 출혈은 간경변의 중요한 합병증으로 사망률이 20-50%에 이른다. 식도정맥류 출혈에 대한 지혈 효과를 높이기 위해 내시경적 결찰술과 함께 약물치료로 vasopressin과 nitroglycerin의 병용요법이 많이 사용되어 왔으나 전신 혈역학적 부작용이 있다는 단점이 있다. Terlipressin은 기존의 vasopressin에 비해 혈관 수축이 더 강력하고 꾸준히 저혈장 농도를 유지함으로써 심박출량 감소나 심근경색 등 전신 혈역학적 부작용이 적다는 장점이 있다. 이에 저자들은 응급실로 내원한 급성 식도정맥류 출혈 환자에서 내시경적 결찰술과 함께 vasopressin＋nitroglycerin 병용 투여 혹은 terlipressin 단독 투여한 각 환자군에서 그 치료 효과와 부작용을 비교하고자 하였다. 대상과 방법: 급성 식도정맥류 첫 출혈 환자 45 명을 대상으로 후향적으로 조사하였다. 내시경적 결찰술과 vasopressin＋nitroglycerin 병용 치료군(V＋N군) 24 예, 내시경적 결찰술과 terlipressin 치료군(T군) 21예로 분류하여 초기 지혈률, 재출혈률 및 합병증 등을 비교하였다. Vasopressin, nitroglycerin과 terlipressin은 응급실 내원 시 식도 정맥류 출혈이 의심된 경우 즉시 투여 하였으며, 출혈 후 24시간 이내에 내시경적 결찰술을 시행한 환자를 대상으로 했다. 식도정 맥류 출혈의 과거력이 있어 정맥류에 대한 내시경 치료를 받았던 환자, 베타차단제, 비스테로이드성 소염진통제나 항응고제의 복용력이 있는 환자, 위정맥류 출혈이나 식도 정맥류 외에 다른 출혈병소가 있는 환자, 출혈성 질환이나 중한 심폐 질환을 가진 환자, 지혈을 위해 내시경 시행 전 Sangstaken-Blakemore 관을 삽입한 자는 대상에서 제외하였다. 초기 지혈 성공은 내시경적 결찰술 후 48시간 동안 출혈의 증후가 없는 경우로 하였다. 재출혈은 경과 중 흑색 변이나 토혈이 있거나 혈색소 수치가 2 이상 감소한 경우로 하였다. 결과: 1) V＋N군과 T군 간의 성별, 나이, 원인, 생체징후, 혈색소치, 혈소판수, 총빌리루빈 수치, 복수 유무, 간성 혼수에서 유의한 차이는 없었다. 2) 초기 지혈 성공률은 V＋N 군이 83.3%(21/24명 ), T군이 90.1%(19/21명) 이었다. 재출혈률은 V＋N군이 33.3%, T 군이 28.6%로 두군간에 통계적으로 유의한 차이는 없었다. 3) 부작용은 V＋N군에서 저나트륨혈증 2 예, 심한 복통 2예, 흉통 1예, 서맥 1예가 있었으나 T군에서 관찰되는 부작용은 없었다. 4) V＋N군에서 2예는 지혈에 성공했으나 간부전으로 사망했으며, 1 예는 패혈증, 1 예는 재출혈로 사망했다. T군에서는 사망 예가 없었다. 결론: 본 연구에서 V+N군과 T 군 간에 초기 지혈률과 재출혈률에 있어서 유의한 차이는 없었다. 그러나 부작용의 발생과 사망에 있어서 V＋N군이 상대적으로 높았다. 따라서, 급성 식도정맥류 출혈에서 내시경적 결찰술과 함께 terlipressin 투여가 기존에 사용되어오던 vasopressin과 nitroglycerin의 병용 투여를 대체할 수 있을 것으로 생각된다.
Screening for Occult Cancer in Unprovoked Venous Thromboembolism
Authors: Marc Carrier, Alejandro Lazo-Langner, Sudeep Shivakumar, Vicky Tagalakis, Ryan Zarychanski, Susan Solymoss, Nathalie Routhier, James Douketis, Kim Danovitch, Agnes Y. Lee, Gregoire Le Gal, Philip S. Wells, Daniel J. Corsi, Timothy Ramsay, Doug Coyle, Isabelle Chagnon, Zahra Kassam, Hardy Tao, Marc A. Rodger
Journal: New England Journal of Medicine (2015)

Venous thromboembolism may be the earliest sign of cancer. Currently, there is a great diversity in practices regarding screening for occult cancer in a person who has an unprovoked venous thromboembolism. We sought to assess the efficacy of a screening strategy for occult cancer that included comprehensive computed tomography (CT) of the abdomen and pelvis in patients who had a first unprovoked venous thromboembolism.We conducted a multicenter, open-label, randomized, controlled trial in Canada. Patients were randomly assigned to undergo limited occult-cancer screening (basic blood testing, chest radiography, and screening for breast, cervical, and prostate cancer) or limited occult-cancer screening in combination with CT. The primary outcome measure was confirmed cancer that was missed by the screening strategy and detected by the end of the 1-year follow-up period.Of the 854 patients who underwent randomization, 33 (3.9%) had a new diagnosis of occult cancer between randomization and the 1-year follow-up: 14 of the 431 patients (3.2%) in the limited-screening group and 19 of the 423 patients (4.5%) in the limited-screening-plus-CT group (P=0.28). In the primary outcome analysis, 4 occult cancers (29%) were missed by the limited screening strategy, whereas 5 (26%) were missed by the strategy of limited screening plus CT (P=1.0). There was no significant difference between the two study groups in the mean time to a cancer diagnosis (4.2 months in the limited-screening group and 4.0 months in the limited-screening-plus-CT group, P=0.88) or in cancer-related mortality (1.4% and 0.9%, P=0.75).The prevalence of occult cancer was low among patients with a first unprovoked venous thromboembolism. Routine screening with CT of the abdomen and pelvis did not provide a clinically significant benefit. (Funded by the Heart and Stroke Foundation of Canada; SOME ClinicalTrials.gov number, NCT00773448.).
Abstract 28: Increased Expression Of Mitochondrial Inducible Nitric Oxide Synthase By Heat Shock Protein Hsp22/h11 Kinase Promotes Oxidative Phosphorylation In Mammalian Heart
Authors: Hongyu Qiu, Eman Rashed, Christophe Depre
Journal: Circulation Research (2014)

Aims: Stress-inducible heat shock protein 22 (Hsp22) confers protection against ischemia through induction of the inducible isoform of nitric oxide synthase (iNOS). Hsp22 over-expression in vivo significantly stimulates cardiac mitochondrial respiration, whereas Hsp22 deletion in vivo shows a reciprocal effect. It has also been shown in Drosophila that Hsp22 is expressed in the mitochondria that depends on its N-terminal domain. We hypothesized that Hsp22-mediated regulation of mitochondrial function is dependent upon its mitochondrial translocation together with iNOS. Methods and Results: Adenoviruses harboring either the full coding sequence of Hsp22 (Ad-WT-Hsp22) or a mutant lacking a 20 amino acid putative N-terminal mitochondrial localization sequence (Ad-N20-Hsp22) were generated, and infected in rat neonatal cardiomyocytes. Compared to β-Gal control, Ad-WT-Hsp22 accumulated in mitochondria by 2.5 fold (P&lt;0.05), reduced chelerythrine-induced apoptosis by 60% (P&lt;0.01), and increased oxygen consumption rate by 2-fold (P&lt;0.01). This latter effect was abolished upon addition of the specific iNOS inhibitor, 1400W. Ad-WT-Hsp22 significantly increased global iNOS expression by about 2-fold (P&lt;0.01), and also increased its mitochondrial localization by 2.5 fold vs β-gal (P&lt;0.05). Upon comparable over-expression, the Ad-N20-Hsp22 mutant did not show significant mitochondrial translocation, protection against apoptosis or stimulation of mitochondrial respiration. Although Ad-N20-Hsp22 did increase global iNOS expression by 6-fold it did not significantly promote iNOS mitochondrial translocation. Conclusion: Translocation of both Hsp22 and iNOS to the mitochondria is necessary for the stimulation of oxidative metabolism and protection against apoptosis.
Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.
Authors: Eric Van Cutsem, Kun-Huei Yeh, Yung-Jue Bang, Lin Shen, Jaffer A. Ajani, Yu-Xian Bai, Hyun Cheol Chung, Hong-Ming Pan, Keisho Chin, Kei Muro, Yeul Hong Kim, Heind Smith, Chiara Costantini, Sara Musalli, Syed Rizvi, Tarek Sahmoud, Atsushi Ohtsu
Journal: Journal of Clinical Oncology (2012)

LBA3 Background: The prognosis for patients with AGC after failure of first-line chemotherapy is poor. Currently, there is no level 1 evidence established for second-line treatment. EVE inhibits the PI3K/Akt/mTOR pathway, a key regulator of cell proliferation, metabolism, and angiogenesis, and has shown efficacy against AGC in preclinical and phase I/II studies. Methods: In a randomized, double-blind, multicenter, phase III study, patients age ≥18 years with confirmed AGC and disease progression after 1 or 2 lines of systemic chemotherapy were randomized 2:1 to oral EVE 10 mg/d plus best supportive care (BSC) or placebo (PBO) plus BSC. Randomization was stratified by region (Asia vs rest of world) and previous lines of chemotherapy (1 vs 2). Study drug was discontinued upon progression or unacceptable toxicity. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), and safety. The final analysis was performed when 526 deaths occurred. Results: A total of 656 patients from 23 countries were enrolled from Jul 2009 to Dec 2010; 439 were randomized to EVE, 217 to PBO. Baseline characteristics were well balanced between arms; 73.6% were men, 55.3% were enrolled in Asia, 47.7% received 1 previous line of chemotherapy, and 50.6% had a gastrectomy. Median OS was 5.39 months with EVE vs 4.34 months with PBO (HR, 0.90; 95% CI, 0.75-1.08; P=0.1244). Median PFS per local investigator assessment was 1.68 months with EVE vs 1.41 months with PBO (HR, 0.66; 95% CI, 0.56-0.78; p&lt;0.0001). Six-month PFS estimates were 12.0% with EVE and 4.3% with PBO. OS and PFS results were consistent across the various subgroups. ORR (95% CI) was 4.5% (2.6%-7.1%) with EVE vs 2.1% (0.6%-5.3%) with PBO. The most common grade 3/4 adverse events were anemia (16.0% with EVE vs 12.6% with PBO), decreased appetite (11.0% vs 5.6%), and fatigue (7.8% vs 5.1%). Conclusions: EVE monotherapy did not significantly improve OS in patients with AGC previously treated with 1 or 2 lines of systemic chemotherapy. EVE did improve PFS. Results for OS and PFS were consistent across the various subgroups. The safety profile was consistent with that previously observed with EVE.
Quality of psychosocial care in oncology: A national survey of oncologists
Authors: W. F. Pirl, A. Muriel, V. Hwang, J. Greer, A. Kornblith, D. B. Greenberg, K. Donelan, J. Temel, L. Schapira
Journal: Journal of Clinical Oncology (2007)

6561 Background: Little is known about the quantity and quality of psychosocial care being delivered by oncologists in the United States. This study surveyed oncologists about their management of psychosocial distress, using the National Comprehensive Cancer Network (NCCN) guidelines for psychosocial distress as a standard. Availability of mental health services and routine screening for distress were used as measures of quality care. Methods: A random sample of 1,000 oncologists in the United States belonging to ASCO were surveyed with an anonymous e-mail and mail-based questionnaire between 9/05 and 7/06. Initial univariate analyses were used to test differences in frequencies among groups using Chi-square for categorical variables, and t-tests and ANOVA for continuous variables. Variables that were associated with reported routine screening at the .05 significance level in the univariate analyses were entered into a logistic regression model to determine independent predictors of screening. Results: Forty-six percent (448/965) of oncologists responded. Almost two-thirds (63.6%, 285/448) practiced in community settings, 27.2% (122/448) at cancer centers, and 6.9% (31/448) in hospitals. Only half (50.3%, 95% CI 45.7–54.9%; 225/448) reported having any mental health services affiliated with their practice. Availability differed by practice setting, with cancer centers having the most and community having the least (P&lt;.001). Only one-third (32.3%, 144/445) reported being at least somewhat familiar with the NCCN guidelines. Two-thirds (65.0%, 95% CI 60.6–69.4%; 290/446) reported routinely screening for distress, but only 14.3% (64/447) use a screening instrument. Availability of mental health services, knowledge of NCCN guidelines, experience, time, certainty about identifying distress and being female were independent predictors of reported screening. Conclusion: Only 36.4% (95% CI 34.1–38.7%; 162/445) reported both of our measures of quality care, available mental health services and routine screening for distress. While the majority report routinely screening for distress, only a small percentage follow NCCN guidelines by using a screening instrument, and only half report having mental health services available. No significant financial relationships to disclose.
TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial
Authors: S. Costa, G. Von Minckwitz, C. Jackisch, G. Raab, J.-U. Blohmer, A. Loehr, B. Gerber, H. Eidtmann, J. Hilfrich, M. Kaufmann
Journal: Journal of Clinical Oncology (2004)

825 Background: As previously shown, response to 2 cycles of preoperative chemotherapy might enhance the pathologic complete remission rate (pCR) in patients (P) with operable primary breast cancer (OPBC) up to 4-fold (Von Minckwitz, SABCS 2003). We prospectively address this observation in the Gepartrio trial where chemotherapy is randomly allocated according to early tumor response. Methods: P with OPBC (T ≥ 2 cm by palpation) or locally advanced breast cancer are treated with 2 cycles TAC (Docetaxel 75mg/m2, Doxorubicin 50 mg/m2, Cyclophosphamide 500 mg/m2 day 1, q21). In case of significant tumor reduction (≥ 50% reduction measured by breast ultrasound, ORR), P are randomized to receive either 4 or 6 additional cycles TAC. Non responders are randomized to either additional 4 cycles TAC or 4 cycles NX (Vinorelbine 25 mg/m2 day 1 + 8, Capecitabine 2000 mg/m2 day 1–14, q21) (TAC-NX). Primary endpoints are pCR-rate for responders and ORR for non-responders. Secondary objectives are response at surgery, toxicity, compliance, and the rate of cCR/cPR after 2 cycles TAC. Results: 907 P (791 operable and 116 non-operable) of 2014 planned P with a median clinical tumor size of 4.0 cm have been recruited since July 2002. ORR was 74.4% (589 P). Most patients had T2-tumors (71%), with grading 2 (60.7%), histologic type was ductal-invasive in 76.7%, and the axillary lymph node status was N0 in 55%. Estrogen and/or progesterone receptors were positive in 70.1%. Treatment was discontinued in 28 P (3%) due to toxicity (13 P), non-compliance (9 P), tumor progression (3 P) and of other causes in 3 P. 209 serious adverse events have been reported (204 after TAC and 5 after NX). Grade III/IV neutropenia is the most frequently reported toxicity (8.6% associated with TAC and 0.9% with NX). Conclusions: TAC is a highly effective preoperative treatment in breast cancer. NX seems to be associated with a better toxicity profile compared to TAC. Response after 2 cycles can identify P with a high or minimal chance of achieving a pCR and might be considered as an in vivo chemosensitivity test. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Aventis
Abstract 12914: Explaining the Heritability in Lipoprotein Subclasses Using Detailed Genetic Information in Known Lipid Loci
Authors: Taru Tukiainen, Johannes Kettunen, Antti J Kangas, Pasi Soininen, Mika Ala-Korpela, Marjo-Riitta Jarvelin, Samuli Ripatti
Journal: Circulation (2012)

Genome-wide association studies (GWAS) have identified over 100 loci that are associated with TC, TG, LDL-C, HDL-C or lipoprotein subclasses, and further fine-mapping studies have shown that many o...
Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
Authors: L R Prosnitz, L R Farber, D S Kapp, J Scott, J R Bertino, J J Fischer, E C Cadman
Journal: Journal of Clinical Oncology (1988)

From 1969 through 1982, 184 patients with advanced Hodgkin's disease (HD) were treated with combined modality therapy (CMT) at Yale University. The data were reanalyzed in November 1986, with a mean follow-up of 10 years. The patient population consisted of 102 newly diagnosed stages IIIB and IV patients, and 82 patients who had relapsed after initial radical radiotherapy. From 1969 through 1978, the treatment program was induction chemotherapy with nitrogen mustard, vincristine, vinblastine, procarbazine, and prednisone (MVVPP) for three cycles (6 months) followed by low-dose radiation (1,500 to 2,500 cGy) for patients who had achieved complete remission (CR), to all disease sites present before the onset of chemotherapy. From 1978 to 1982, selected "poor-risk" advanced-stage patients received nitrogen mustard, vincristine, procarbazine, prednisone plus Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), bleomycin, vinblastine, and dacarbazine (MOPP-ABVD) induction chemotherapy, while the remaining patients were randomized between MVVPP and MOPP. One hundred fifty-one patients have achieved CR (82%); 23 (15%) of these 151 have relapsed, with the remaining 128 patients in continuous CR. A total of 62 patients have died, 45 due to HD, and 17 due to other causes. Twelve of these 17 patients died of second malignancies. The 15-year actuarial survival of all patients is 54%. It is 71% if deaths due only to HD are considered. Within the overall group of advanced HD patients, age and multiple extranodal sites of involvement continue to constitute adverse risk factors. The three drug programs used were all equivalent. No improvement resulted from the use of MOPP-ABVD in the poor-risk patients. These results compare favorably with those recently published by the National Cancer Institute (NCI). CMT resulted in an approximate 20% improvement in survival with no increase in second malignancies when compared with chemotherapy alone.
Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma
Authors: Ethan Toumishey, Angeli Prasad, Gregory S. Dueck, Neil Chua, Daygen Finch, Douglas A. Stewart, Darrell J. White, Richard H. van der Jagt, James B Johnston, Andrew R Belch, Tony Reiman
Journal: Blood (2013)